Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Fine needle aspiration biopsy proves increased T-lymphocyte proliferation in tumor and decreased metastatic infiltration after treatment with doxorubicin bound to PHPMA copolymer carrier

J. Betka, O. Hovorka, J. Boucek, K. Ulbrich, T. Etrych, B. Rihova,

. 2013 ; 21 (7) : 648-61.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14051105

INTRODUCTION: Fine needle aspiration biopsy (FNAB) is an easy method with an option of repetitive withdrawal of cell material. METHODS: First, mice were inoculated with mouse T-lymphoma, after 10 d the samples from tumor, lymph nodes and spleen gained by FNAB and excision were analyzed by flow cytometry. Tumor progression was compared to the control group simultaneously. Then, 10 d after tumor cell inoculation free doxorubicin (DOX) or different PHPMA DOX conjugates were injected. Cell material was analyzed to detect subpopulations of lymphocyte infiltrate, and levels of cytokines in correlation with progression or regression of the disease. RESULTS: FNAB has no influence on the tumor's growth or survival of experimental animals. After treatment with PHPMA conjugates there was a significant increase of T-lymphocyte subpopulations in tumor microenvironment compared to controls or free DOX, but only in mice with confirmed macroscopic regression of tumor within two weeks. Mice treated with conjugates showed significantly lower cancer infiltration of lymph nodes and spleen. CONCLUSION: FNAB provides a great benefit to in vivo monitoring of cell changes directly in the tumor after treatment. The number of infiltrating T-lymphocytes increases in correlation with consecutive tumor eradication after treatment with PHPMA. This proves that not only direct cytotoxic but also imunostimulating effect are necessary for successful treatment.

000      
00000naa a2200000 a 4500
001      
bmc14051105
003      
CZ-PrNML
005      
20140411122131.0
007      
ta
008      
140401s2013 enk f 000 0|eng||
009      
AR
024    7_
$a 10.3109/1061186X.2013.792345 $2 doi
035    __
$a (PubMed)23621109
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Betka, Jaroslav
245    10
$a Fine needle aspiration biopsy proves increased T-lymphocyte proliferation in tumor and decreased metastatic infiltration after treatment with doxorubicin bound to PHPMA copolymer carrier / $c J. Betka, O. Hovorka, J. Boucek, K. Ulbrich, T. Etrych, B. Rihova,
520    9_
$a INTRODUCTION: Fine needle aspiration biopsy (FNAB) is an easy method with an option of repetitive withdrawal of cell material. METHODS: First, mice were inoculated with mouse T-lymphoma, after 10 d the samples from tumor, lymph nodes and spleen gained by FNAB and excision were analyzed by flow cytometry. Tumor progression was compared to the control group simultaneously. Then, 10 d after tumor cell inoculation free doxorubicin (DOX) or different PHPMA DOX conjugates were injected. Cell material was analyzed to detect subpopulations of lymphocyte infiltrate, and levels of cytokines in correlation with progression or regression of the disease. RESULTS: FNAB has no influence on the tumor's growth or survival of experimental animals. After treatment with PHPMA conjugates there was a significant increase of T-lymphocyte subpopulations in tumor microenvironment compared to controls or free DOX, but only in mice with confirmed macroscopic regression of tumor within two weeks. Mice treated with conjugates showed significantly lower cancer infiltration of lymph nodes and spleen. CONCLUSION: FNAB provides a great benefit to in vivo monitoring of cell changes directly in the tumor after treatment. The number of infiltrating T-lymphocytes increases in correlation with consecutive tumor eradication after treatment with PHPMA. This proves that not only direct cytotoxic but also imunostimulating effect are necessary for successful treatment.
650    _2
$a zvířata $7 D000818
650    _2
$a antitumorózní látky $x aplikace a dávkování $x chemie $x terapeutické užití $7 D000970
650    12
$a jehlová biopsie $7 D001707
650    12
$a proliferace buněk $7 D049109
650    _2
$a doxorubicin $x aplikace a dávkování $x chemie $x terapeutické užití $7 D004317
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    12
$a metastázy nádorů $7 D009362
650    _2
$a experimentální nádory $x farmakoterapie $x patologie $7 D009374
650    _2
$a kyseliny polymethakrylové $x chemie $7 D011109
650    _2
$a T-lymfocyty $x patologie $7 D013601
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Hovorka, Ondrej $u -
700    1_
$a Boucek, Jan $u -
700    1_
$a Ulbrich, Karel $u -
700    1_
$a Etrych, Tomas $u -
700    1_
$a Rihova, Blanka $u -
773    0_
$w MED00008008 $t Journal of drug targeting $x 1029-2330 $g Roč. 21, č. 7 (2013), s. 648-61
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23621109 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140401 $b ABA008
991    __
$a 20140411122221 $b ABA008
999    __
$a ok $b bmc $g 1018241 $s 849685
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 21 $c 7 $d 648-61 $i 1029-2330 $m Journal of drug targeting $n J Drug Target $x MED00008008
LZP    __
$a Pubmed-20140401

Najít záznam

Citační ukazatele

Nahrávání dat...

Možnosti archivace

Nahrávání dat...